论文部分内容阅读
目的:分析DC-CIK细胞免疫治疗联合放疗治疗中晚期宫颈癌的临床疗效。方法:筛选2012年10月-2015年1月于我院治疗的中晚期宫颈癌患者62例,根据入院先后时间分组,常规组(32例,放疗治疗)和实验组(30例,DC-CIK细胞免疫治疗+放疗治疗),对比两组患者的生活质量以及生存率情况。结果:实验组患者生活质量优于常规组,P<0.05;且实验组的1年、2年和3年生存率(96.7%、73.3%、60.0%)高于对照组的(93.8%、62.5%、46.9%),P<0.05。结论:治疗中晚期宫颈癌可采取DC-CIK细胞免疫治疗联合放疗治疗,疗效明显,对提升生活质量及生存率具有积极的意义,值得推广应用。
Objective: To analyze the clinical efficacy of DC-CIK cell immunotherapy combined with radiotherapy in the treatment of advanced cervical cancer. Methods: Sixty-two patients with advanced cervical cancer who were treated in our hospital from October 2012 to January 2015 were enrolled in this study. According to the time of admission, the patients in the conventional group (32 cases, radiotherapy) and the experimental group (30 cases, DC-CIK Cell immunotherapy + radiotherapy), quality of life and survival rate of two groups were compared. Results: The quality of life in the experimental group was better than that in the control group (P <0.05). The 1-year, 2-year and 3-year survival rates in the experimental group were significantly higher than those in the control group (96.7%, 73.3%, 60.0% %, 46.9%), P <0.05. Conclusion: The treatment of advanced cervical cancer can be DC-CIK cellular immunotherapy combined with radiotherapy, the effect is obvious, to improve the quality of life and survival rate has a positive meaning, it is worth to promote the application.